Cryo-Cell International Inc. (OTCMKTS:CCEL) CEO Mark L. Portnoy sold 10,500 shares of the firm’s stock in a transaction on Thursday, December 28th. The shares were sold at an average price of $9.36, for a total transaction of $98,280.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Cryo-Cell International Inc. (OTCMKTS:CCEL) traded up $0.31 during mid-day trading on Friday, reaching $9.67. 3,495 shares of the company’s stock were exchanged, compared to its average volume of 2,731. The firm has a market capitalization of $66.48, a PE ratio of 32.23 and a beta of -0.47. The company has a current ratio of 0.87, a quick ratio of 0.85 and a debt-to-equity ratio of -0.43. Cryo-Cell International Inc. has a 12-month low of $4.20 and a 12-month high of $9.43.

Cryo-Cell International (OTCMKTS:CCEL) last announced its quarterly earnings results on Monday, October 16th. The company reported $0.08 EPS for the quarter. The firm had revenue of $6.90 million during the quarter. Cryo-Cell International had a net margin of 9.87% and a negative return on equity of 16.87%.

TRADEMARK VIOLATION NOTICE: “Cryo-Cell International Inc. (CCEL) CEO Sells $98,280.00 in Stock” was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at

Cryo-Cell International Company Profile

Cryo-Cell International, Inc is engaged in cellular processing and cryogenic storage. The Company’s segments include cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacture of Prepacyte CB units, the processing technology used to process umbilical cord blood stem cells.

Receive News & Ratings for Cryo-Cell International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryo-Cell International and related companies with's FREE daily email newsletter.